DoW Peer Reviewed Medical, Clinical Trial Award
Can you apply?
This grant is for researchers conducting clinical trials supported by Army-funded Congressionally Directed Medical Research Programs. Eligible organizations include academic institutions, research centers, hospitals, and nonprofit organizations conducting federally fundable clinical research. The program supports trials addressing specific FY26 topic areas and strategic goals established by Congress. Projects must complete all preclinical work before award start and cannot use funds for animal studies or finalizing interventions.
Three funding levels match trial phases: Level 1 for phase 0–1 trials (under 100 participants), Level 2 for phase 2 trials (under 300 participants), and Level 3 for phase 3 trials (300+ participants). Applicants may request a Planning Phase (up to 12 months) for regulatory activities, or apply with Clinical Trial Only if approvals are already in place.
Program description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.
Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.
Supports three funding levels, each offered with and without a Planning Phase:
Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.
Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.
Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $94.5M to fund approximately 9 Clinical Trial Award applications with total cost caps of $800,000 for the planning phase of a Clinical Trial with Planning Phase, $6M for Funding Level 1, $10M for Funding Level 2, and $20M for Funding Level 3 per award. The maximum period of performance is 4 years for the clinical trial, and 12 months for the planning phase. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (federal grant application form)
- Project Narrative (clinical trial protocol and design)
- Budget and Budget Narrative
- Institutional commitment or letters of support
- IRB approval or documentation of IRB review status
- FDA regulatory documentation (IND, IDE, or equivalent status)
Program contact
- 👤 Christopher L Baker Grants Officer
- 📧 help@eBRAP.org
- 📞 3016192332
Funding track record
Recent awards under CFDA 12.420 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$2,265,729,366
-
$800,631,761
-
$74,531,880
-
$67,205,571
-
$53,718,832
-
$34,191,124
-
$24,907,742
-
$21,394,379
-
$19,100,256
-
$19,002,641
Top States by Funding
- MD 10 awards $3,150.1M
- NC 11 awards $132.3M
- FL 8 awards $99.8M
- CA 11 awards $99.3M
- MA 7 awards $75.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 12.420). How funding has trended year over year.
| 2024 | $1,483,968,520 | |
| 2025 | $1,201,153,417 |
FAQ
Who can apply for this clinical trial award?
Academic institutions, research centers, hospitals, and nonprofit organizations are eligible. Specific institutional eligibility requirements apply; contact USAMRAA for current guidance.
What is the deadline?
The application deadline is September 22, 2026. Awards will be made by September 30, 2027.
Can I include a planning phase?
Yes. Clinical Trial with Planning Phase (up to 12 months) supports regulatory activities before the trial starts. Clinical Trial Only is available if regulatory approvals already exist.
What are the funding levels and caps?
Level 1 (under 100 participants): up to $6M. Level 2 (under 300): up to $10M. Level 3 (300+): up to $20M. Planning Phase: up to $800K.
How long is the award period?
Clinical trials are funded for up to 4 years. Planning phases are up to 12 months.
💡 Tips for applicants
- Align your trial with one of the FY26 congressionally directed topic areas; off-topic applications have low success rates.
- Submit with Clinical Trial Only status if regulatory approvals are final; these applications are typically prioritized.
- Complete all preclinical and animal study work before award start; this is non-negotiable.
- Match your participant count carefully to the correct funding level; misalignment signals misunderstanding.
- Request a Planning Phase only if genuine regulatory or planning work remains; reviewers scrutinize these requests.
⚠️ Common mistakes
Applying with animal studies or incomplete preclinical work planned for the award period will result in rejection. Misalignment with congressionally directed FY26 topic areas is a primary reason for unfunded applications. Requesting Planning Phase when regulatory approvals are already in place weakens competitiveness.
Similar grants
- OPEN Rural Community Health Integration2026 — New York State Department of Health
- OPEN FY26 Bureau of Land Management Rangeland Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Cultural and Paleontological Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Youth Conservation Corps – Bureau wide — Bureau of Land Management
- OPEN Infertility Training Center — Office of the Assistant Secretary for Health